Clinical Trials Browser

Phase 1 × N,N-dicyclohexyl-isoborneol-10-sulfonamide × Clear all

NCT07133997 2026-03-13

Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia

Phase 1 Not yet recruiting

26 enrolled

Lymphoid

Burkitt Lymphoma

NCT04872790 2026-02-10

Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia

Phase 1 Recruiting

20 enrolled

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute

NCT02568553 2025-11-26

Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma

Phase 1 Completed

35 enrolled

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT02879695 2025-08-15

Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia

Phase 1 Active not recruiting

28 enrolled 16 charts

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute

NCT03340766 2024-10-17

HARBOUR

Phase 1 Completed

31 enrolled 29 charts

Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT00274742 2015-01-16

Safety Study of the Bispecific T-cell Engager Blinatumomab (MT103) in Patients With Relapsed NHL

Phase 1 Completed

76 enrolled 15 charts

Lymphoid

Bites and Stings, Lymphoma, Non-Hodgkin, Recurrence